EVISA Print | Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:

US FDA Announces Gadolinium-Based MRI Contrast Agent Warning

(15.09.2010)


Background:
GBCAs are intravenous drugs used in diagnostic imaging procedures to enhance the quality of magnetic resonance imaging or magnetic resonance angiography.
NSF is a rare and potentially fatal disorder characterized by the hardening of the skin, eyes and internal organs. The association of NSF with GBCAs can be traced back to 2006 when the FDA reported cases of NSF in renal failure patients. Since then, the regulator has been monitoring the effects of all GBCAs for their potential to cause this serious disease.

FDA warning:
The FDA released a mandate on September 9, 2010, which requires a black box warning label–the strongest in the industry– to be issued on the use of specific GBCAs. This directive calls for a label update for these GBCAs due to the risk of nephrogenic systemic fibrosis (NSF) if they are used in patients with kidney disease.

Seven MRI drugs containing gadolinium have been approved by the FDA, and all can cause NFS in patients with kidney disease. But three in particular are “chemically more unstable” than the others, according to the FDA, meaning they are more likely to release the toxic chemical. These three are Bayer Healthcare’s Magnevist, General Electric Healthcare’s Omniscan and Covidien’s Optimark.

Rather than pull the drug, the FDA is requiring stronger labeling that instructs physicians to use the drug only on patients who have healthy kidneys. Healthcare professionals should screen patients prior to administration of a GBCA to identify those with acute kidney injury or chronic, severe, kidney disease. See the Drug Safety Communication for the complete list of recommendations to healthcare professionals and patients.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 



Related Information

 FDA: Deptember 12, 2007: Important Drug Warning for Gadolinium-Based
Contrast Agents

 FDA: Information on Gadolinium-Containing Contrast Agents

BfArm: Main information on contrast media containing gadolinium: Risk of nephrogenic systemic fibrosis (NSF) (in German)


Related EVISA Resources

 EVISA Link Database: Toxicity of Gadolinium compounds
 EVISA Materials Database: Gadolinium Materials


Related News

EVISA News, March 25, 2010: Publication on the separation of Gd-based contrast agents awarded
EVISA News, May 4, 2009: Gadolinium speciation analysis in search for the cause of nephrogenic systemic fibrosis (NSF)

EVISA News, April 17, 2009: Gadolinium-based MRI contrast agents found intact in the outlet of a waste water treatment plant




last time modified: September 15, 2010



Comments






Imprint     Disclaimer

© 2003 - 2010 by European Virtual Institute for Speciation Analysis ( EVISA )